Trial Profile
Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet Autotransplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Alpha 1-antitrypsin
- Indications Pancreas transplant rejection
- Focus Therapeutic Use
- 10 Aug 2023 Planned End Date changed from 1 Jul 2026 to 1 May 2025.
- 01 Jan 2023 Primary endpoint (Maximal acute C-peptide response to glucose (ACRmax)) has been met, as per Results published in the Pancreatology.
- 01 Jan 2023 Results (n=43) assessing efficacy of etanercept and alpha-1 antitrypsin to improve autologous islet engraftment, published in the Pancreatology.